Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review
Objectives: For advanced ovarian cancer (OC), particularly OC with HR-deficient, surgery combined with adjuvant chemotherapy and maintenance therapy with PARPi/bevacizumab is the standard effective first-line treatment regimen. However, the clinical benefit of therapy for HR-proficient advanced OC i...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2025-08-01
|
| シリーズ: | Gynecologic Oncology Reports |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2352578925001109 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|